Comparative Pharmacology
Head-to-head clinical analysis: KETEK versus NEOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETEK versus NEOBIOTIC.
KETEK vs NEOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
Telithromycin 800 mg orally once daily for 7-10 days.
1 g intravenously every 12 hours.
None Documented
None Documented
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Antibiotic, Ketolide
Antibiotic